Aurinia Pharmaceuticals Inc. Website

Aurinia Pharmaceuticals Inc.

NasdaqGM-AUPH

Company Overview

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.

  • Name

    Aurinia Pharmaceuticals Inc.

  • CEO

    Peter S. Greenleaf

  • Website

    www.auriniapharma.com

  • Sector

    Biotechnology

  • Year Founded

    1993

Company Statistics

Profile

  • Market Cap

    —

  • EV

    —

  • Shares Out

    —

  • Revenue

    —

  • Employees

    —

Margins

  • Gross

    —

  • EBITDA

    —

  • Operating

    —

  • Pre-Tax

    —

  • Net

    —

  • FCF

    —

Returns (5Yr Avg)

  • ROA

    —

  • ROTA

    —

  • ROE

    —

  • ROCE

    —

  • ROIC

    —

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    —

  • P/E

    —

  • PEG

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

Financial Health

  • Cash

    —

  • Net Debt

    —

  • Debt/Equity

    —

  • EBIT/Interest

    —

Growth (CAGR)

  • Rev 3Yr

    —

  • Rev 5Yr

    —

  • Rev 10Yr

    —

  • Dil EPS 3Yr

    —

  • Dil EPS 5Yr

    —

  • Dil EPS 10Yr

    —

  • Rev Fwd 2Yr

    —

  • EBITDA Fwd 2Yr

    —

  • EPS Fwd 2Yr

    —

  • EPS LT Growth Est

    —

Dividends

  • Yield

    —

  • Payout

    —

  • DPS

    —

  • DPS Growth 3Yr

    —

  • DPS Growth 5Yr

    —

  • DPS Growth 10Yr

    —

  • DPS Growth Fwd 2Yr

    —

What's happening

Nov 12, 2025 - Dec 12, 2025

Aurinia Pharmaceuticals Faces Challenges Amid Market Fluctuations

  • A downgrade from Leerink Partners raised concerns about Aurinia's future performance.
  • Speculation surrounding a potential buyout sparked temporary investor interest.
  • The stock underperformed relative to both the S&P 500 and the Health Care sector.

Over the past month, Aurinia Pharmaceuticals Inc (AUPH) experienced a slight decline of 1.3%. This performance is notably lower than the S&P 500's return of 0.7%, indicating an underperformance of 2.0% relative to this benchmark index. The company's struggles can be attributed to fluctuating market conditions that have affected investor confidence.

A significant factor contributing to this decline was a downgrade from Leerink Partners on December 3rd, which changed its rating from "Outperform" to "Market Perform." This reassessment included a new price target set at $16.00 and resulted in an immediate drop in share value by 7.5%. Such negative analyst ratings created bearish sentiment around AUPH’s operational outlook and strategic direction.

Despite these challenges, there were signs of potential recovery towards the end of the month when reports suggested strong signals for an imminent buyout of Aurinia Pharmaceuticals Inc., particularly due to their absence from JPM26 being viewed as critical in this speculation. On December 10th, this news led to a modest gain of 1.2%, reflecting renewed interest among investors who perceived positive implications regarding acquisition possibilities.

However, these optimistic indicators could not fully offset earlier losses stemming from ongoing skepticism about AUPH’s prospects within broader industry dynamics affecting similar companies in the Health Care sector (XLV), which itself saw declines but only by -3.2%. Overall, while moments hinting at recovery emerged late in December due to acquisition speculations, persistent bearish influences primarily dictated AUPH's trajectory throughout the month.

Aurinia Pharmaceuticals Inc underperformed the Health Care (XLV) sector by -3.2%.

NasdaqGM:AUPH